# Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

> **NCT04830397** · PHASE2 · COMPLETED · sponsor: **Qlaris Bio, Inc.** · enrollment: 84 (actual)

## Conditions studied

- Primary Open Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** QLS-101
- **DRUG:** Timolol Maleate

## Key facts

- **NCT ID:** NCT04830397
- **Lead sponsor:** Qlaris Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-31
- **Primary completion:** 2022-02-17
- **Final completion:** 2022-02-17
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04830397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04830397, "Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04830397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*